Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

This study has been withdrawn prior to enrollment.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:
First received: November 1, 1999
Last updated: October 18, 2013
Last verified: October 2013

RATIONALE: Determination of genetic markers for acute lymphoblastic leukemia and acute promyelocytic leukemia may help identify patients with this disease and help predict the outcome of treatment.

PURPOSE: Diagnostic study of genetic markers in adult patients who have acute lymphoblastic leukemia or acute promyelocytic leukemia.

Condition Intervention
Genetic: reverse transcriptase-polymerase chain reaction
Other: flow cytometry

Study Type: Interventional
Study Design: Primary Purpose: Diagnostic
Official Title: Molecular Genetic Features of Acute Lymphoblastic Leukemia

Resource links provided by NLM:

Further study details as provided by Alliance for Clinical Trials in Oncology:

Primary Outcome Measures:
  • Disease-free survival [ Designated as safety issue: No ]
  • Overall survival [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Association of novel genes or micorRNAs with other biomarkers [ Designated as safety issue: No ]
  • Clinical significance of minimal residual disease (MRD) as defined by BCR-ABL [ Designated as safety issue: No ]
  • Clinical significance of MRD as defined by W T-1 [ Designated as safety issue: No ]
  • Blood and bone marrow specimen comparison on the quantitative measurement of MRD [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: April 1999
Detailed Description:


  • Perform quantitative polymerase chain reaction (PCR) using known leukemia specific markers in diagnostic bone marrow specimens and correlate pre-treatment copy number with other biologic and molecular features, clinical response, and treatment outcomes of patients with previously untreated acute lymphoblastic leukemia (ALL) or acute promyelocytic leukemia (APL).
  • Evaluate the expression of novel genes or microRNAs implicated in disease pathogenesis and treatment response in pretreatment blood and bone marrow specimens of these patients and correlate these findings with other biological features and treatment outcome.
  • Evaluate the clinical significance of sequential quantitative MRD measurements using real-time quantitative PCR and/or flow cytometry during and following treatment and correlate these findings with efficacy of novel treatment approaches and other biological and clinical prognostic features.
  • Compare the measurement of MRD in blood with bone marrow specimens in sequential remission specimens.

OUTLINE: Blood and bone marrow samples are collected from patients periodically.

Samples are examined for the p190 and p210 BCR-ABL and WT-1 transcripts using reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the DNA and for marginal residual disease (MRD) via flow cytometric analysis.

Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.

PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study over 5 years.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of 1 of the following diseases:

    • Acute lymphoblastic leukemia (ALL)

      • Patients enrolled on CALGB-19802 or any CALGB treatment trials for previously untreated ALL, must be enrolled on this trial
    • Acute promyelocytic leukemia (APL)

      • Patients enrolled on SWOG-S0521 or SWOG-S0535 for previously untreated APL must be enrolled on this trial



  • Adult

Performance status:

  • See Disease Characteristics

Life expectancy:

  • See Disease Characteristics


  • See Disease Characteristics


  • See Disease Characteristics


  • See Disease Characteristics


  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003861

  Show 51 Study Locations
Sponsors and Collaborators
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Study Chair: Wendy Stock, MD University of Chicago
  More Information

No publications provided

Responsible Party: Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier: NCT00003861     History of Changes
Other Study ID Numbers: CDR0000067025  U10CA076001  CALGB-9862 
Study First Received: November 1, 1999
Last Updated: October 18, 2013
Health Authority: Unspecified

Keywords provided by Alliance for Clinical Trials in Oncology:
untreated adult acute lymphoblastic leukemia
adult acute promyelocytic leukemia (M3)

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Promyelocytic, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immune System Diseases
Immunoproliferative Disorders
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on February 11, 2016